(Q44158244)

30 November 2017

title

Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease (English)

1 reference

eradication of infectious diseases

30 November 2017

1 reference

1 reference

Fendrick AM

1

1 reference

30 November 2017

Chey WD

2

1 reference

30 November 2017

Margaret N

3

1 reference

30 November 2017

Palaniappan J

4

1 reference

30 November 2017

Fennerty MB

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

American Journal of Medicine

30 November 2017

published in

1 reference

30 November 2017

volume

107

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

133-136

1 reference

Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

Eradication of Helicobacter pylori in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

Can therapy even be denied for Helicobacter pylori infection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900196-5

10.1016/S0002-9343(99)00196-5

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference